Letter to the editor regarding: "Tirofiban vs. aspirin in patients with acute ischemic stroke: A meta-analysis of randomized clinical trials".

The article by De Oliveira et al. presents an insightful systematic review and meta analysis comparing intravenous tirofiban and oral aspirin in acute ischemic stroke (AIS) patients. It has sparked substantial discussions among my colleagues and me, particularly regarding the optimal circumstances for administering intravenous tirofiban in AIS patients ineligible for reperfusion therapies.